Efficacy/Safety of Cilta-Cel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-Up From CARTITUDE-2 Cohort D

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 16-1-2026, 3:17